Maja J A de Jonge

6PUBLICATIONS
90CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 30, 2025
Improving Shared Decision-Making in Early Phase Clinical Trials and Palliative Care: A Prospective Study on the Impact of an Online Value Clarification Tool Intervention.

Liza G G van Lent, Julia C M van Weert, Maja J A de Jonge

|Mar 17, 2025
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.

Johann S de Bono, Anja Williams, Ignacio Melero

|Jul 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia

|Apr 17, 2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

Birgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek

|Feb 02, 2024
Patient values in patient-provider communication about participation in early phase clinical cancer trials: a qualitative analysis before and after implementation of an online value clarification tool intervention.

Liza G G van Lent, Mirte van der Ham, Maja J A de Jonge

|Nov 08, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.

Yvette Drew, Jae-Weon Kim, Richard T Penson

Pageof 1

Frequent Collaborators

4 joint publications

Eelke H Gort

2 joint publications

Carin C D van der Rijt

2 joint publications

Jade M van Berge Henegouwen

2 joint publications

Birgit S Geurts